This study is the first demonstration that FRβ-expressing macrophages are present in the atherosclerotic lesions and that intravenous administration of FRβ immunotoxin markedly reduced the progression of atherosclerotic lesions in both the early and advanced stages of atherosclerosis. This evidence concerns the gene FOLR2 and atherosclerosis.